title: Inhibiting insulin resistance mechanisms by DTS phytocompound: an experimental study on metabolic syndrome-prone adipocytes.
abstract: The present study was designed to determine whether DTS a phytocompound endowed with antioxidant properties, could beneficially modulate nitric oxide (NO) production stimulated by lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) in adipocytes. Combined stimulation (CS-treatment) exerted by using 5 microg/ml of LPS together with 100 ng/ml of TNF-alpha significantly enhanced NO production in 3T3-L1 adipocytes. Preincubation of the adipocytes with DTS (10-30 mM) inhibited such phenomenon in a dose-dependent fashion. The production of NO was decreased by 52% at the concentration of 30mM of DTS. The decrease in NO production by DTS was associated also with a decrease in inducible nitric oxide synthase (iNOS) protein and iNOS mRNA expression. Nuclear factor-kappa B (NF-kappaB) was significantly enhanced by CS-treatment, while the pretreatment with 30 mM of DTS prevented the activity by 27%. IL-6 production in 3T3-L1 adipocytes was markedly increased by CS stimulus, and the enhanced secretion of IL-6 was suppressed in a dose-dependent manner by DTS. These results suggest that DTS regulates iNOS expression and NO production in adipocytes through the modulating activation of NF-kappaB and may have a potential clinical application within protocols designed for treating metabolic syndrome. (www.actabiomedica.it).
authors: Dept. of Internal Medicine, University of Catania, Catania, Italy.
authors: Roberto
authors: R
authors: Catanzaro
authors: Aldo
authors: A
authors: Lorenzetti
authors: Flavio
authors: F
authors: Allegri
authors: Hariom
authors: H
authors: Yadav
authors: Umberto
authors: U
authors: Solimene
authors: Ajit K
authors: AK
authors: Kumaraju
authors: Emilio
authors: E
authors: Minelli
authors: Claudio
authors: C
authors: Tomella
authors: Ascanio
authors: A
authors: Polimeni
authors: Francesco
authors: F
authors: Marotta
mesh_terms: D017667:Adipocytes / Q000378:metabolism* / Q000473:pathology; D002478:Cells, Cultured; D006801:Humans; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016328:NF-kappa B / Q000096:biosynthesis / Q000187:drug effects; D009569:Nitric Oxide / Q000096:biosynthesis*; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis / Q000187:drug effects*; D018384:Oxidative Stress / Q000187:drug effects*; D013449:Sulfonamides / Q000494:pharmacology*; D013830:Thiadiazoles / Q000494:pharmacology*
chemical_list: C448309:2-(2,2-dichloroacetylamino)-1,3,4-thiadiazole-5-sulfonamide; D016328:NF-kappa B; D013449:Sulfonamides; D013830:Thiadiazoles; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II